Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Published . Updated .
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Directly affected
- LLY Eli Lilly
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Source: CNBC Top
How far Eli Lilly (LLY) has moved since 25 Sep 2026
Since the first closing price after “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s,” Eli Lilly (LLY) is +4.64%. The S&P 500 fund (SPY) is +0.15% over the same days, a +4.49% difference versus the market.
Official trades in Eli Lilly (LLY) around 25 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 4 days after publication, inside 30 days. The filing is listed beside the story “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 14 days before publication, inside 30 days. The filing is listed beside the story “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s.”
- Rohit Khanna buy Eli Lilly (LLY) ($1,001 - $15,000). That is 21 days before publication, inside 30 days. The filing is listed beside the story “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 53 days before publication, inside 60 days. The filing is listed beside the story “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 57 days before publication, inside 60 days. The filing is listed beside the story “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 57 days before publication, inside 60 days. The filing is listed beside the story “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Eli Lilly (LLY)
Companies tied to this story
- LLY Eli Lilly
For “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s,” Eli Lilly (LLY) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names ELI LILLY & CO in the headline; GA resolved that company to LLY
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 25 Sep 2026 story “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 25 Sep 2026 story “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
In “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Eli Lilly (LLY)
“Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s” (25 Sep 2026) reaches Eli Lilly (LLY) through this story.
The link for Eli Lilly (LLY) is this: The reported development directly names ELI LILLY & CO in the headline; GA resolved that company to LLY
Also listed, Acadia Healthcare (ACHC): GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Eli Lilly (LLY)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. LLY traded between 1131.55 and 1275.56 across 20 sessions. The latest close on file is 1240.65.
What the saved facts support for Eli Lilly (LLY)
46 out of 100
“Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.